Study design
bleeding, miscarriage, spotting, pain
ADVERSE EVENTS, BLEEDING, MISCARRIAGE, SECONDARY
This clinical trial was performed on 90 patients referred to the gynecology and obstetrics clinic affiliated with Jahrom University of Medical Sciences with miscarriage and a gestational age below 12 weeks from March to July 2020.The sample size was calculated according to Paris et al. [After taking a comprehensive history from each patient, the data obtained was registered in the relevant code sheets. After being matched in gestational age, the next step involved randomly allocating patients into three distinctive groups. To reduce outcome assessment bias in this study, the radiologist examined the images without prior knowledge of the patient’s status, thus ensuring impartial evaluation. Subsequently, the patients were checked for success rates of pregnancy tissue expulsion as the primary outcome and bleeding, pain, and spotting as a secondary outcome. The protocol of this study was approved by the ethical committee of Jahrom University of Medical Sciences issued with code No.: IR.JUMS.REC.1396.143 was further registered in the Iranian registry of clinical trials with code ID IRCT20200122046221N1. It is worth mentioning that all patients recruited in this study have provided their written informed consent to the researchers, and all probable adverse events and benefits of the research were explained to them.